These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2479966)

  • 1. Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope.
    Goudsmit J; Zwart G; Bakker M; Smit L; Back N; Epstein L; Kuiken C; d'Amaro J; de Wolf F
    Res Virol; 1989; 140(5):419-36. PubMed ID: 2479966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1.
    Goudsmit J; Bakker M; Smit L
    Res Virol; 1989; 140(5):405-18. PubMed ID: 2479965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.
    Meloen RH; Liskamp RM; Goudsmit J
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1505-12. PubMed ID: 2471813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.
    Profy AT; Salinas PA; Eckler LI; Dunlop NM; Nara PL; Putney SD
    J Immunol; 1990 Jun; 144(12):4641-7. PubMed ID: 1693639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
    Goudsmit J; Bakker M; Smit L; Meloen RH
    J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.
    Devash Y; Matthews TJ; Drummond JE; Javaherian K; Waters DJ; Arthur LO; Blattner WA; Rusche JR
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):307-16. PubMed ID: 2340200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: a later variant isolated from the same host.
    Davis D; Trischmann H; Stephens DM; Lachmann PJ
    J Med Virol; 2001 Jul; 64(3):207-16. PubMed ID: 11424106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.
    Goudsmit J; Thiriart C; Smit L; Bruck C; Gibbs CJ
    Vaccine; 1988 Jun; 6(3):229-32. PubMed ID: 3166553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope specificity, antibody-dependent cellular cytotoxicity, and neutralizing activity of antibodies to human immunodeficiency virus type 1 in autoimmune MRL/lpr mice.
    Lombardi V; Placido R; Scarlatti G; Romiti ML; Mattei M; Mariani F; Poccia F; Rossi P; Colizzi V
    J Infect Dis; 1993 Jun; 167(6):1267-73. PubMed ID: 7684755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.